Nxera Pharma Forecasts FY2026 Revenue of JPY48,800M
Nxera expects core operating profit of JPY22,800M and operating profit of JPY15,700M. The forecast assumes a US$100M AbbVie upfront payment is recognized in Q4, subject to transaction completion by year-end and auditor agreement.
Story updates
08:47:01 AM UTC
SquawkNews
Nxera granted AbbVie exclusive worldwide rights to develop and commercialize NXE0033744 for IBD, receiving $100M upfront and eligible for up to $1.37B in milestones plus tiered royalties. The upfront is expected to be recognized as Q4 2026 revenue, subject to auditor agreement.Material DetailsConte…
Nxera expects FY2026 revenue of JPY48,800M, core operating profit of JPY22,800M and operating profit of JPY15,700M. The forecast assumes a US$100M AbbVie upfront payment is recognized in Q4, subject to transaction completion by year-end and auditor agreement.Material DetailsContext by AI AnalystThi…